The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Autor: Wesley Buckingham, Tressa Hood, Maj-Britt Jensen, Torsten O. Nielsen, Sean Ferree, Bent Ejlertsen, Jens Ole Eriksen, Namratha Ram, Pernille Wehn, Anne-Vibeke Lænkholm
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Receptor
ErbB-2
medicine.medical_treatment
Receptor
ErbB-2/metabolism
0302 clinical medicine
Surgical oncology
Breast/pathology
Antineoplastic Combined Chemotherapy Protocols
CMF
PAM50
Breast
Mastectomy
Hazard ratio
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Cyclophosphamide/therapeutic use
Fluorouracil
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Predictive value of tests
Female
Chemotherapy
Adjuvant/methods
medicine.drug
Research Article
Adult
medicine.medical_specialty
Cyclophosphamide
Methotrexate/therapeutic use
Breast Neoplasms
Breast Neoplasms/genetics
Fluorouracil/therapeutic use
lcsh:RC254-282
Risk Assessment
Disease-Free Survival
Neoplasm Recurrence
Local/diagnosis
03 medical and health sciences
Breast cancer
Predictive Value of Tests
Internal medicine
medicine
Humans
Risk Assessment/methods
Retrospective Studies
Chemotherapy
business.industry
Gene Expression Profiling
medicine.disease
Adjuvant chemotherapy
030104 developmental biology
Methotrexate
Clinical Trials
Phase III as Topic
Premenopause
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Breast neoplasms
Gene Expression Profiling/methods
Neoplasm Recurrence
Local
business
Follow-Up Studies
Zdroj: Breast Cancer Research : BCR
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Jensen, M B, Lænkholm, A V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast Cancer Research, vol. 20, no. 1, 79 . https://doi.org/10.1186/s13058-018-1012-0
Jensen, M-B, Lænkholm, A-V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast cancer research : BCR, vol. 20, 79 . https://doi.org/10.1186/s13058-018-1012-0
ISSN: 1465-542X
1465-5411
DOI: 10.1186/s13058-018-1012-0
Popis: Background: The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal patients with high-risk breast cancer. Methods: Prosigna assays were performed on the NanoString platform in tumors from participants in Danish Breast Cancer Group (DBCG) 77B, a four-arm trial that randomized premenopausal women with high-risk early breast cancer to no systemic treatment, levamisole, oral cyclophosphamide (C) or cyclophosphamide, methotrexate and fluorouracil (CMF). Results: In total, this retrospective analysis included 460 women (40% of the 1146 randomized patients). The continuous Prosigna ROR score was prognostic in the no systemic treatment group (unadjusted P
Databáze: OpenAIRE
Externí odkaz: